Abstract
Heart failure is characterized by poor survival, a loss of catecholamine reserve and cellular structural remodeling in the form of disorganization and loss of the transverse tubule network. Indeed, survival rates for heart failure are worse than many common cancers and have not improved over time. Tadalafil is a clinically relevant drug that blocks phosphodiesterase 5 with high specificity and is used to treat erectile dysfunction. Using a sheep model of advanced heart failure, we show that tadalafil treatment results in a marked improvement in symptom-free survival, reverses transverse tubule loss and restore cardiac myocyte systolic calcium transient amplitude and the hearts chronotropic and contractile response to catecholamines. These effects are independent of changes in myocardial cGMP content and are associated with upregulation of both monomeric and dimerized forms of protein kinase G and of the cGMP hydrolyzing phosphodiesterase 2 and 3. We propose that the molecular switch for the loss of transverse tubules in heart failure and their restoration following tadalafil treatment involves the BAR domain protein Amphiphysin II (BIN1) and the restoration of catecholamine sensitivity is through reductions in G-protein receptor kinase 2, protein phosphatase 1 and protein phosphatase 2A abundance following phosphodiesterase 5 inhibition.
(197 words) Impaired responsiveness to catecholamines is a hallmark of the failing heart and is detectable both in vivo and in isolated ventricular myocytes 1, 2 . The mechanisms responsible for the attenuated catecholamine effects in heart failure (HF) are varied and include reduced adenylate cyclase activity and enhanced G protein receptor kinase (GRK2) and intracellular protein phosphatase activity (PP1 and PP2A) which together lead to a decrease in cAMP dependent signaling and impaired PKA-dependent target phosphorylation 1, 3, 4 . Given the functional distribution of β-adrenergic receptors (β-ARs) and G-proteins across the surface sarcolemma and transverse tubule (TT) membrane [5] [6] [7] a further factor proposed to contribute to impairment of the β-adrenergic signalling cascade in HF is the reduction of transverse tubule (TT) density seen in many pre-clinical models and human HF [8] [9] [10] [11] .
In addition to the classical cAMP-dependent process, the myocardial response to catecholamine stimulation is also regulated by the cGMP-PKG signaling axis consisting of the β3-AR / soluble guanylate cyclase (sGC) and natriuretic peptide / particulate guanylate cyclase (pGC) pathways (reviewed by Tsai and Kass 12 ). The outcome of cGMP dependent activation depends on the source of activating cGMP; that activated by sGC inhibiting the β-AR response whereas pGC derived cGMP has no effect 13, 14 . Beyond the role of PKG, GRK2 and protein phosphatases in determining the outcome of β-AR stimulation, the intracellular pools of cAMP and cGMP are also differentially regulated by PDEs suggesting highly compartmentalized regulation of the cyclic nucleotides and thus catecholamine responsiveness of the healthy ventricular myocardium e.g. [15] [16] [17] [18] .
Given the negative impact of acute PDE5 inhibition on the inotropic and lusitropic response to catecholamines and the established loss of catecholamine reserve in HF it is somewhat surprising that an emerging body of evidence suggests PDE5 inhibition is clinically cardioprotective in type II diabetes 19 , left ventricular hypertrophy 20 and in patients with HF with reduced ejection fraction (systolic HF) 21 . Similarly, in experimental models, PDE5 inhibition shows cardioprotective effects in pulmonary hypertension 22 , myocardial infarction [23] [24] [25] [26] and following aortic banding 27 . However, in each of these cases PDE inhibitor treatment was commenced either before or given concurrently with the disease intervention. Such an experimental approach complicates interpretation of whether the intervention is therapeutically useful in a setting of established disease or acting by preventing disease development. In most 28, 29 , but not all 30 experimental studies where PDE5 inhibition has been commenced once some degree of left ventricular remodeling has occurred the findings remain supportive of a cardioprotective effect. However, in the 'positive' studies data on survival outcomes is absent and the extent of disease progression to symptomatic heart failure is unclear.
For example, the systolic Ca 2+ transient in aortic banded animals is at least as large as that observed in sham animals and the Ca 2+ transient response to β-AR stimulation is greater in the aortic banded than sham animals 29 . Neither the maintained baseline Ca 2+ transient nor the augmented response to β-AR stimulation are consistent with numerous experimental and clinical studies of symptomatic heart failure e.g. 1, 2, 31 .
Given these considerations the hypothesis examined is that phosphodiesterase 5 inhibition is beneficial in systolic heart failure through restoration of catecholamine responsiveness. As such, the primary aim of the present study was to determine if PDE5 inhibitor treatment, instigated at an advanced disease stage once contractile dysfunction and attenuated catecholamine responsiveness are established, is capable of reversing these effects and conferring a symptom-free survival benefit. The secondary aim of the study was to determine if any contractile, symptom-free survival and catecholamine responsiveness changes were associated with structural (TT) remodeling and the underlying molecular mechanisms of such TT remodeling. The final aim of the study was to determine the underlying mechanisms that contribute to the restoration of catecholamine responsiveness. The major findings are that PDE5 inhibition with tadalafil markedly enhances symptom-free survival, partially reverses contractile dysfunction and restores catecholamine responsiveness in vivo. At the cellular level, PDE5 inhibition restored systolic calcium. These changes are associated with a restoration of TT density but β-AR abundance (β1 and β2) remained unaltered.
However, downstream regulators of catecholamine signalling including GRK2, PKG, PDE2, PDE3, PP1 and PP2A were all differentially regulated by HF and PDE5 inhibition.
Our findings also implicate the BAR domain protein amphiphysin II (AmpII aka BIN1) as a key driver of the TT changes seen in response to HF and PDE5 inhibitor treatment.
Results

PDE5 inhibition improves symptom-free survival and enhances cardiac contractility in vivo
Of the 27 animals randomly assigned to the tadalafil treatment group, all remained free of signs of heart failure to the completion of the study (day 49, Figure 1A ) and one was found dead on day 19 of treatment; notably there were no prior signs of heart failure (including lethargy, dyspnea, weight loss, tussis) and on post-mortem examination the pacing lead was found to have perforated the right ventricular wall and pulmonary congestion was not evident. Conversely, 34 of 42 untreated animals developed signs of heart failure before day 49 and were therefore humanely killed for subsequent in vitro experiments. Thus, tadalafil treatment markedly improved symptom-free survival (p < 0.001) yielding a Cox's proportional hazard ratio of 0.026 ± 0.03 (95 % CI, 0.003 -0.19; p < 0.001). There was no difference in body weight between the 42 untreated (32.0 ± 1.1 kg) and 26 tadalafil treated animals with weight data (31.6 ± 1.3 kg) and, as such, body weight was not a significant covariate having a hazard ratio of 1.02 ± 0.03 (95 % CI, 0.97 -1.07; p = 0.44). In the tadalafil treated HF animals (N = 13) the total plasma tadalafil content determined by mass spectrometry was 269 ± 39 µg/l and plasma tadalafil protein binding measured as 93 ± 0.6 % and thus in good agreement with that in healthy human subjects 32 . Thus, the nadir free tadalafil concentration in HF plasma following 3 weeks of daily dosing (20 mg daily) was 51 ± 8 nmol/l.
We next sought to determine if the increase in symptom-free survival following tadalafil treatment was associated with any changes in cardiac contractility or cardiac dimensions. In line with our previous findings 1, [33] [34] [35] left ventricular dilatation and free wall thinning were observed following tachypacing ( Figure 1B & C) . Tadalafil treatment did not reverse left ventricular dilatation but did normalize diastolic wall thickness from its nadir value observed one week after commencement of tadalafil treatment. In sheep the cardiac apex is positioned over the sternum and it is difficult to obtain four chamber apical views in adult animals. Therefore, we used the short axis fractional area change measured at mid papillary muscle level as a surrogate for ejection fraction. Following 4 weeks of tachypacing fractional area change was reduced from pre-pacing values by 43 ± 7 % ( Figure 1D ) in the untreated group and to the same extent in the tadalafil group before treatment commenced (43 ± 3%, p < 0.001; both groups p < 0.001 vs pre-pacing values). However, tadalafil treatment increased fractional area change such that by the end of the study fractional area change was 16 ± 8 % greater than at 4 weeks (p < 0.05) and 35 ± 24 % greater than in the end-stage untreated group (p < 0.01). In agreement with the in vivo contractility findings and our previous study 1 , the amplitude of the systolic calcium transient was reduced by 66 ± 14 % in HF ( Figure 1E , p < 0.05).
However, following tadalafil treatment the amplitude of the systolic calcium transient was 132 ± 32 % of control values (p = 0.49) and therefore was restored to a greater extent than in vivo contractility.
Whilst tadalafil treatment augmented cardiac contractility, improved symptom-free survival and systolic calcium, the additive effects of tadalafil treatment on blood pressure were minimal. Previously we have reported that systolic, diastolic and mean blood pressure decrease in HF 36 ; an observation repeated here (Table 1) . However, tadalafil treatment had no further effect on blood pressure which was indistinguishable from both the 4 week tachypaced and heart failure groups. Thus, the changes in cardiac function associated with tadalafil treatment are not due to changes in peripheral blood pressure.
PDE5 inhibition restores the inotropic and chronotropic response to catecholamine stimulation
Since HF is associated with a reduced responsiveness to β-adrenergic stimulation 1, 33 and impaired catecholamine responses are associated with reduced survival in HF patients 37 we next determined if the improved symptom-free survival following chronic tadalafil treatment was also associated with restoration of catecholamine responsiveness. We first examined cardiac contractile responses to intravenous infusion of the exogenous β-adrenergic agonist dobutamine. Whilst left ventricular fractional area change in dobutamine was attenuated in tadalafil treated animals compared to pre-pacing values it was greater than in both untreated animals following 4 weeks of tachypacing and when signs of (end stage) HF were present ( Figure 1F , p < 0.001). In paired samples (pre-pacing, 4 weeks and tadalafil treated), the absolute fractional area changes ( Figure 1F ) were reflected in a greater response to dobutamine infusion after tadalafil treatment than after 4 weeks of tachypacing ( Figure 1G) indicating that chronic PDE5 inhibition in HF augments catecholamine sensitivity.
Furthermore, tadalafil treatment also improved the chronotropic response to dobutamine ( Figure 1H ). As we have reported previously in a separate study 33 , HF attenuated the chronotropic response to dobutamine. In pre-paced animals, 5 µg/kg/min dobutamine shortened RR interval by 36 ± 10 % (p < 0.01) yet had no effect following 4 weeks of tachypacing or in end-stage HF (5.4 ± 8 % and 3.8 ± 2 % respectively). Conversely, at this infusion rate RR interval shortened by 26 ± 6 % in the tadalafil treated animals (p < 0.01). To further understand the attenuated chronotropic response, we also investigated the dose-response to dobutamine in a cohort of animals at three time points; pre-pacing, 4 weeks of tachypacing (but before tadalafil treatment commenced) and following 3 weeks of tadalafil treatment ( Figure 1I ). It is clear that the sensitivity to dobutamine was reduced at 4 weeks of tachypacing and partially restored toward control values following tadalafil treatment. Assuming that the maximal achievable heart rate is equal to that in pre-paced animals treated with 10 µg.kg -1 .min -1 dobutamine, the calculated EC50 concentration of dobutamine is 3.6, 34.4 and 10.7 µg.kg -1 .min -1 in the pre-pacing, 4 weeks tachypaced and tadalafil treated groups respectively (p < 0.005). In addition to improving several in vivo measures of cardiac function and catecholamine sensitivity, chronic PDE5 inhibition also normalized the tachypacing induced increases in NPPB (B-type natriuretic peptide) mRNA (Figure 2A ).
Thus, tadalafil treatment at least partially restores both the inotropic and chronotropic response to catecholamines that are lost in HF and reverses increases in mRNA abundance of the widely accepted marker of HF, B-type natriuretic peptide.
The impact of PDE5 inhibition on regulators of cGMP and the β-adrenergic signalling cascade
There was no change in the abundance of PDE5A mRNA ( Figure 2B ) or cGMP levels in myocardial homogenates ( Figure 2C ) in HF or following tadalafil treatment. Whilst unaltered PDE5 mRNA levels in HF have been reported previously 29, 38 , the unchanged myocardial cGMP content following tadalafil treatment was initially surprising.
However, examining known regulators of cGMP in HF and following tadalafil treatment we found an increase in total, monomeric (75 kDa) and dimerized (150 kDa) PKG ( Figure 2D ). Total and 75 kDa PKG abundances were not different between the 4-week paced, HF and tadalafil groups. However, for the 150 kDa dimer of PKG, abundance was greater in the tadalafil group compared to the 4-week paced group and tended to an increase when compared to the HF group (p = 0.053). Moreover, tadalafil treatment augmented the abundance of the cGMP hydrolyzing phosphodiesterases PDE2 and PDE3 ( Figure 2E & F) . Thus, the increased abundance of PKG, through inhibition of sGC 39 and stimulation of PDE5 15 , coupled with elevated levels of the cGMP hydrolyzing PDEs 2 & 3 provide a plausible explanation for the unchanged myocardial cGMP content despite chronic tadalafil treatment.
In the next experiments we sought to elucidate the impact of chronic PDE5 inhibition in HF on key regulators of catecholamine signalling in the heart. We found no difference in β1 or β2 adrenergic receptor abundance in whole heart homogenates following four weeks of tachypacing, in HF or following tadalafil treatment ( Figures 3A & B) . In agreement with our previous findings 1 , in HF the protein abundance of G protein coupled receptor kinase GRK2 and protein phosphatases PP1 and PP2A was increased ( Figure 3C-E) . The increase in GRK2, PP1 and PP2A was established by 4 weeks of tachypacing, reaffirming adrenergic dysfunction is established prior to PDE5 inhibitor treatment in this study. Importantly, chronic tadalafil treatment resulted in a reduction in protein abundance for each of these regulators of β-adrenergic signalling to either the same level (GRK2, PP1) or lower (PP2A) than in control hearts thus mechanistically linking PDE5 inhibition with the enhanced catecholamine responses noted in vivo.
PDE5 inhibition restores the transverse tubule network in heart failure
Since the β1-AR and β2-AR are functionally distributed on the TT membrane and surface sarcolemma 5, 7 we sought to determine if the restored response to the β-AR agonist dobutamine following tadalafil treatment was associated with changes in TT density or organisation in ventricular myocytes ( Figure 4A ). To quantify changes in TT density we have adopted two approaches; i) determination of the distance 50 % of voxels (3 dimensional pixels) are from their nearest membrane (TT or surface membrane) in all three imaging planes, termed 'half-distance' 8, 34 ( Figure 4A .b.) and, ii) determination of the fractional area of the cytosol occupied by TT's in the imaging plane, termed 'fractional area' 8, 34 . In agreement with our previous work 8 and others e.g. 9,10,40 heart failure resulted in a decrease in ventricular TT density of 19 ± 5 % measured using the half distance ( Figure 2B ; p < 0.001) and 26 ± 5 % using fractional area methodologies ( Figure 4C ; p < 0.001). Importantly, these changes in TT density had occurred by 4 weeks of tachypacing and therefore the TT density reduction observed in HF was 
Potential molecular mechanisms responsible for changes in TT density in heart failure and reversal by PDE5i treatment
Although the control of TT turnover remains poorly understood we next sought to identify potential molecular mechanisms responsible for the restoration of TTs following tadalafil treatment. We examined protein abundance of four putative regulators of TT turnover AmpII (BIN1), junctophilin 2 (JPH2), titin capping protein (TCAP) and myotubularin 1 (MTM1). Of these, JPH2 ( Figure 5A ) and TCAP ( Figure 5B) showed no change in abundance with disease duration or tadalafil treatment whereas MTM1 abundance was increased equally above control in the 4 week tachypaced, HF and tadalafil treated animals ( Figure 5C , all p < 0.05). Conversely, AmpII protein abundance was reduced from control levels in both the 4 week tachypaced and HF groups where TT density is reduced (Figure 5D .a; p < 0.05) and restored to control levels in the tadalafil treated group in line with the restoration of TTs. Moreover, AmpII abundance was also greater in the tadalafil group than both the 4 week tachypaced and HF groups (p < 0.05). The relationship between TT density and AmpII protein abundance is examined in Figure 5D .b-c. As we have shown previously 8 , TT density is correlated with AmpII protein abundance during the development of HF and following treatment with tadalafil (p < 0.05).
Whilst our present data (e.g. Figure 5D ) and previous studies 8, 41 have shown a correlation between AmpII abundance and TT density, there remains some uncertainty over which isoforms of AmpII (BIN1) are expressed in cardiac muscle and drive the formation of TTs in cardiac myocytes. We therefore sought firstly to determine which AmpII isoforms are present within the ovine myocardium. Using RT-PCR approaches and amplifying the variably expressed regions between exons 6 and 18 of AmpII we identified 3 major amplicons in the ovine myocardium (Fig 6A) . From amplicon size and subsequent sequence verification we identified the 'skeletal', exon 11 containing v8 Figure 6D , p < 0.001). The summary data of Figure 6E demonstrates that AmpII-C-mKate2 expression in NRVMs lead to a robust increase in the fractional area of cells occupied by TTs (59 ± 3 fold, p < 0.001). Finally, we also confirmed that AmpII was capable of driving de novo tubule formation in human iPSC CMs and that these cells also normally lack a discernible tubular network ( Figure 6F -H) .
Discussion
The main findings of the present study investigating the impact of chronic PDE5 inhibition on cardiac function and structure in heart failure are fourfold: i) PDE5 inhibition prevents the development of the signs of heart failure; ii) PDE5 inhibition restores systolic calcium and catecholamine responsiveness; iii) t-tubule density is reduced in heart failure and fully restored to control levels by PDE5 inhibition and, iv) changes in expression of the putative t-tubule regulator AmpII are correlated with changes in t-tubule density and AmpII drives de novo tubule formation in ventricular myocytes. Importantly, in this study we demonstrate that PDE5 inhibition reverses rather than prevents the heart failure dependent changes in cellular structure and catecholamine responsiveness as both the reduction in TT density and loss of catecholamine responsiveness are already present before PDE5 inhibition is commenced.
PDE5 inhibition mediated reverse remodeling in heart failure.
This study shows a dramatic impact of PDE5 inhibition on symptom free survival that is effective once advanced cardiac dysfunction has developed before PDE5 inhibition commences. The observed symptom free survival effects are also reflected by normalization of B-type natriuretic peptide mRNA levels within the myocardium. The delayed administration of PDE5 inhibition used here distinguishes this study from the majority of previous studies investigating PDE5 inhibition in HF where treatment was initiated simultaneously with, or prior to, disease initiation [22] [23] [24] [25] [26] [27] . Additionally, where earlier studies have implemented delayed PDE5 inhibitor treatment, these appear to have been at a far less advanced stage of HF than in this study based on contractility measurements or the response to catecholamine stimulation [28] [29] [30] 38 . Thus, this study adds to a growing weight of evidence on the effectiveness of PDE5 inhibition in treating systolic HF and demonstrates reversal of key elements of the disease process that are evident when cardiac dysfunction is at an advanced stage.
Whilst changes in B-type natriuretic peptide mRNA are observed, the PDE5 inhibition mediated effects on HF progression occur in the absence of changes in PDE5A mRNA and cGMP levels within the myocardium. Previous studies have also noted no change in PDE5A abundance in preclinical HF models 29, 38 and Hiemstra et al, using a porcine model, reported no change in myocardial cGMP content following tadalafil treatment 38 .
In the present study we investigated potential mechanisms that could explain the lack of change in the global cGMP content of the myocardium and found that PKG (monomer, dimer and total levels) and the cGMP hydrolyzing phosphodiesterases PDE2 and PDE3 were augmented following tadalafil treatment. We suggest therefore that the changes in PKG, PDE2 and PDE3 may underlie the lack of a global change in cGMP, yet, there may still remain sub-cellularly restricted pools of elevated cGMP that may influence distinct signalling pathways and underpin the inotropic, chronotropic and 'survival' effects seen with tadalafil treatment.
PDE5 inhibition in heart failure: effects on cardiac function and catecholamine responsiveness.
The first consideration of the effects of tadalafil treatment in heart failure is that of offtarget effects. Tadalafil is structurally distinct from other commonly used PDE5 inhibitors (sildenafil, vardenafil) and shows substantially greater (> 1000 fold) specificity for PDE5 over other PDEs than both sildenafil and vardenafil with the exception of PDE11 where the selectivity ratio (PDE5 IC50 : PDE11 IC50) is between 7.1 and 40 [43] [44] [45] [46] . However, the absence of PDE11 in cardiac myocytes 47 together with the lack of any obvious neurological disturbance or myalgia (PDE11 dependent side-effects) would suggest that despite the plasma concentration of tadalafil used (~ 50 nmol/l) causing complete inhibition of PDE5 (IC50 range 0.94 -9.4 nmol/l) 43, 48 , the approximate 40 %, inhibition of PDE11 is not underpinning the cardioprotective effects observed in the present study. The development of PDE11 specific antagonists or use of lower doses of tadalafil in future studies would enable this to be conclusively determined.
The main observation in the present study is that the profound symptom-free survival benefit of tadalafil treatment was demonstrated when significant cardiac dysfunction was already present. Of the previous studies examining the effects of PDE5 inhibition in heart disease few have objectively assessed the impact of PDE5 inhibition on development (survival) of left-sided heart failure 27 . However, in that study sildenafil treatment was commenced at the time of disease initiation and it is therefore impossible to conclude whether PDE5 inhibition is beneficial once advanced cardiac disease has been established. Moreover, whilst the development of heart failure in aortic-banded rats was reduced by sildenafil treatment 27 the magnitude of the effect was considerably less than that observed here following tadalafil treatment. Further work is therefore required to determine if the survival benefits are specific to tadalafil or are a PDE5 inhibitor class effect.
In those studies where PDE5 inhibition has been started at varying time points following disease initiation there is indeed evidence of attenuated deterioration in function or some reversal of extant dysfunction 28, 30, 49, 50 . However, in each of these cases symptomfree survival and catecholamine response data are absent. Conversely, in those studies where the systolic calcium transient or adrenergic responsiveness has been measured they are either maintained 29 or augmented 38 in the 'heart failure' groups suggesting that the disease stage in these particular studies is relatively early. In comparison, the present study, using a large animal model of tacyhcardic end-stage heart failure, demonstrates a dramatic increase in symptom-free survival where contractile and adrenergic dysfunction are established before the onset of PDE5 inhibitor treatment.
Furthermore, both the contractile dysfunction and attenuated catecholamine response are at least partially reversed by PDE5 inhibitor treatment. A similar restoration of catecholamine reserve in heart failure has been observed experimentally following cardiac resynchronization therapy and suggested to confer improvements in systolic function and long-term survival to this patient group 51 .
In the present study we have investigated the potential mechanisms underpinning the restoration of catecholamine responsiveness following PDE5 inhibition. Whilst we found no change in β1 or β2 adrenergic receptor density in HF or following tadalafil treatment it remains possible that the restoration of TT density with tadalafil treatment is important in directing the sub-cellular aspects β-receptor signalling and thence augmenting cardiac contractility 5, 52 . However, concordant with the restoration of catecholamine sensitivity 1 we observed tadalafil dependent decreases in GRK2, PP1 and PP2A protein abundance which would increase cAMP levels 53 and enhance target phosphorylation including sites on myofilament proteins, phospholamban and the Ltype Ca 2+ channel [54] [55] [56] .
PDE5 inhibition in heart failure: effects on cardiac cellular structure.
Increasing evidence implicates a reduction in TT density as a major factor contributing to cardiac dysfunction in diverse cardiac diseases [8] [9] [10] 22, 34, 40, [57] [58] [59] . In the present study, we also note a decrease in TT density in HF and importantly that this is fully reversed by PDE5 inhibitor treatment. Our findings extend the earlier studies of Huang et al 27 whereby sildenafil treatment commenced concurrently with aortic-banding prevented TT loss and Xie et al 22 where delayed sildenafil treatment partially restored right ventricular TT density in a pulmonary artery hypertension model; although the incomplete recovery of TTs therein may reflect the shorter treatment duration (2 weeks), drug choice (sildenafil) or chamber (right versus left) wall strain differences [60] [61] [62] .
Whilst tadalafil treatment restores TT density, the TTs in this group are equally distributed in the transverse and longitudinal orientations, rather than predominantly transverse orientation seen in control hearts. Previous studies have noted plasticity in TTs and their ability to be restored to varying extents following interventions to reverse HF 27,62-64 although these have not investigated TT orientation in the various intervention arms. Here, we sought to determine if changes in TT density in HF and following tadalafil treatment are correlated with changes in the abundance of proteins implicated in TT biogenesis in striated muscle [65] [66] [67] . Of the putative candidate proteins only one, AmpII, correlates with TT density changes in HF and following tadalafil treatment. AmpII (BIN1) is known to be involved in TT biogenesis in skeletal muscle 68 and in cardiac muscle protein abundance is reduced in HF 8, 41, 63 . Using siRNA gene silencing in cultured adult ventricular myocytes we have shown that AmpII is required for cardiac TT maintenance 8 and Hong et al 42, 69 and more recently, De La Mata et al 70 demonstrated the importance of BIN1 (AmpII) in delivery of L-type Ca channels to TT membranes and TT membrane folding. In the present study, we extend this earlier work and show that AmpII is capable of driving the de novo formation of tubule like structures in both NRVMs and iPSC CMs; model cell types that lack TTs. Importantly, co-labelling with extracellular dye shows that the AmpII driven tubules are patent at the cell surface.
Thus, an emerging body of work highlights the importance of AmpII in the TT biology in the heart and future studies will be required to define the functional significance of AmpII driven TT formation.
Moreover, and in stark contrast to the work of Hong et al using the mouse 42 , we also demonstrate that exon 11 (previously known as exon 10 71 ) containing variants 8 and 4
of AmpII (BIN1) are expressed within the sheep myocardium with variant 8 mRNA being the dominantly expressed isoform and that variant 8 is capable of inducing de novo tubulation in cardiac cells. Further work will be required to elucidate the significance of species differences in AmpII isoform usage and the critical components of AmpII for cardiac muscle TT formation; it may be that, as with chamber differences in TT density, important distinctions exist between laboratory rodents and large mammals including human 8, 34, 72 .
Beyond the correlation between AmpII protein abundance and TT density, we also noted a generalized increase in lipid phosphatase MTM1 protein abundance in the 4 week tachypaced, HF and tadalafil treated animals. In skeletal muscle mutations in MTM1 or altered interaction between MTM1 and a number of binding partners, including AmpII lead to inherited centronuclear myopathies, some of which are associated with cardiomyopathies 73, 74 . Furthermore, MTM1 augments AmpII driven membrane tabulation 74 and MTM1 deficiency leads to reductions in skeletal muscle TT density 75, 76 . Thus, it is possible the increases in MTM1 protein abundance noted in the present study is a compensatory mechanism to maintain TTs in the face of cardiac pathology. However, whether the increase in MTM1 abundance is responsible for the lateralization of TTs in HF and tadalafil treated animals remains to be determined although addressing this in the iPSC and NRVM model systems would be problematic given the inherent disorder of the AmpII driven tubules in these cell types. Finally, there remain the unanswered questions as to whether, i) TT loss is a cause or consequence of HF and, ii) if tadalafil improves cardiac function and this allows TT density to recover or, tadalafil drives TT recovery and thence improves cardiac function. Irrespective of these potential caveats, the dependence of TT maintenance on AmpII 8 and the demonstration in the present study that AmpII drives de novo tubule formation in cardiac myocytes highlights AmpII as a target for future studies. Selectively manipulating AmpII protein abundance in established and evolving cardiac disease states in future studies could resolve this question.
Limitations
There are some limitations to the present study that arise primarily from the lack of suitable reagents exhibiting satisfactory cross-reactivity with sheep. As such, we have been unable to serially assess natriurtetic peptide (BNP or NT-proBNP) levels in plasma to monitor the progression and resolution of HF; however, we do observe a strong upregulation of myocardial NPPB (BNP) mRNA in HF and normalization in the tadalafil treated animals using a single time point assay in each group of experimental animals.
Similarly, we have been unable to determine PDE5A protein abundance and have relied on quantitative PCR based assessments. Whilst our work shows no change in the myocardial cGMP content we cannot rule out the possibility that cGMP is elevated in certain sub-cellular pools and thus mediates the effects of tadalafil treatment that we observe. FRET based sensors may offer some potential to assess sub-cellular cyclic nucleotide pools, their use in sheep would require maintenance of primary cardiac myocytes in extended culture to allow transgene expression and thus significant concerns would arise from cellular de-differentiation and ultrastructural changes that inevitably occur when adult cardiac cells are maintained in culture conditions. A further limitation in the present study arises from the anatomical alignment over the cardiac apex over the sternum in adult sheep and inaccessibility to a suitable imaging window to allow four-chamber apical views for a thorough echocardiographic assessment of ejection fraction and E/A ratios. Furthermore, we have found cardiac conductance catheterization to be of limited use given interference from the pacing lead in the right ventricle. Nevertheless, short axis trans-thoracic imaging is possible and clearly shows marked cardiac dilatation and reduced contractility in HF that is at least partially normalized by tadalafil treatment.
In summary, using a large animal model of end-stage heart failure we have shown that chronic treatment with the PDE5 inhibitor tadalafil leads to a dramatic increase in symptom-free survival. Our data suggests that PDE5 inhibition reverses already established cellular ultra-structural remodeling and impaired catecholamine responses in HF. Given the localization of β-ARs and G-protein coupled regulators of cardiac catecholamine responses across the TT and surface sarcolemma, the recovery of TTs following PDE5 inhibition provides a cellular mechanism for the restoration of catecholamine reserve in tadalafil treated animals and thence the improvement in symptom-free survival.
Methods
Ethical Approval
All experiments were conducted in accordance with The United Kingdom Animals 
In vivo assessments of cardiac contractility and catecholamine responsiveness
During echocardiographic and electrocardiographic assessments tachypacing was stopped for 15 minutes prior to data acquisition. Following in vivo functional assessments tachypacing was continued at 210 bpm.
Cardiac dimensions and contractility were assessed by right para-sternal transthoracic echocardiography (Vivid 7; GE Healthcare, UK) in non-sedated conscious sheep gently restrained in a supine position. Due to the anatomical alignment of the ventricular apex over the sternum in sheep we are unable to obtain satisfactory 4 chamber long axis views and therefore calculate ejection fraction. However, fractional shortening was measured using m-mode imaging at a level proximal to the papillary muscles and fractional area change calculated from short-axis 2d views at the mid-papillary level 33 .
Heart rate was determined from a five-lead ECG (Iox, EMKA Technologies, France). The chronotropic response to β-adrenergic stimulation was assessed as described previously 33 by intravenous infusion of dobutamine hydrochloride (0. 5 -20 µg/kg/min) prepared in 0.9 % saline (Baxter, UK) and delivered using an infusion pump (Harvard Apparatus, UK). Heart rate was determined after 5 mins of dobutamine infusion at each dose and then the infusion rate was doubled to a maximum dose of 20 µg/kg/min or until the heart rate reached 240 bpm.
Transverse tubule staining and quantification
Single left ventricular mid-myocardial myocytes were isolated using a collagenase and protease digestion technique as described in detail previously 1, 8, 34, 79 . Briefly, animals were killed by an overdose of pentobarbitone (200 mg/kg intravenously). Heparin (10,000 units) was also used to prevent coagulation. The heart was rapidly excised and left anterior descending coronary artery cannulated and perfused with collagenase (Worthington Type II, 0.1mg/ml) and protease (from Streptomyces griseus, 0.02 mg/ml) containing solutions and single myocytes dispersed by gentle trituration in a taurine solution containing (in mmol/l): NaCl, 113; taurine, 50; glucose, 11; HEPES, 10; BDM, 10; KCl, 4; MgSO4, 1.2; Na2HPO4, 1.2; CaCl2, 0.1 and BSA, 0.5mg.ml -1 (pH 7.34 with NaOH).
Changes in intracellular Ca 2+ concentration were measured using Fura-2 at 37 o C in cells electrically stimulated at 0.5 Hz as we have described previously 1, 35, 80 .
TT's were visualized by staining with di-4-ANEPPS (4 µmol/l. Invitrogen, UK) as described in detail previously 8, 34, 72 . Stained myocytes were imaged by confocal microscopy (Leica SP2 or Zeiss 7Live; 488 nm excitation and 505 nm long pass emission settings) at 100 nm XY pixel dimensions and 162 nm Z-step size. Images were deconvolved using the microscope specific derived point spread function (PSF) using Huygens Software (Scientific Volume Imaging, Netherlands) 8, 34, 72, 81 . Following background correction and image thresholding the following quantitative assessments of TT's were calculated: i) TT fractional area derived from binarized images as the pixels occupied by TT's as a fraction of the planar cell area (ImageJ. NIH, USA), ii) the distance 50 % of voxels in the cell are from the nearest membrane (TT or surface sarcolemma), hereafter referred to as the half-distance, was determined using custom algorithms written in IDL (Exelisvis, UK) 8, 34, 72 . Images were first interpolated to give the same X, Y, Z spacing ('congrid') and then Euclidean distance maps determined ('morph_distance') and, iii) TT orientation was determined from skeletonized binary images as described previously 8, 59 using the ImageJ plugin 'Directionality'.
mRNA, protein expression and cGMP content analysis
Changes in protein expression were assessed in samples obtained from the same hearts used for in vivo and TT visualization experiments using approaches described in detail previously 1, 8, 35 . Following cardiac excision, a ~ 1 cm 3 region of the posterior left ventricular free wall was removed and snap frozen and stored in liquid nitrogen until analysis. Whole myocardium homogenates (~ 100 mg starting material) were prepared in RIPA buffer with protease and phosphatase inhibitors (0.1 mg/ml phenylmethanesulphonylfluroide, 100 mmol/l sodium orhtovanadate, 1mg/ml aprotonin, 1mg/ml leupeptin) and protein content determined (DC Protein Assay, BioRad, UK). Proteins were separated by PAGE, transferred to nitrocellulose membranes and protein expression determined using the antibodies and blotting conditions outlined in Table 2 . For PKG protein measurements, sample preparation and blots were conducted under non-reducing conditions. Membranes were visualized by chemiluminescence (Syngene, UK) or IR-Dye labeled secondary antibodies (Licor, UK). Previously we determined that the 'classical' housekeeping proteins GAPDH and β-actin have altered expression in various disease states and therefore we normalized expression of our protein of interest to an internal control (IC) common to each blot and total protein transferred to the membrane determined either by Ponceau S staining or REVERT total protein stain (Licor, UK). The IC was derived from a single control sheep (which itself was not included in the present study). Blots were repeated in triplicate on separate occasions and data averaged to minimize any effects due to pipetting or protein transfer errors. Full length blots and validation controls are shown in Supplemental Information ( Figure S1 ).
Total RNA was isolated using Trizol reagent, purified using RNAeasy columns (Qiagen, UK) following manufacturers recommendations. RNA yield and integrity were determined using a Nanodrop (ThermoFisher, UK) and TapeStation (Agilent, UK) instruments respectively. 1 µg total RNA (RIN scores > 7.0) was then reverse transcribed using a high capacity RNA to cDNA kit (Applied Biosystems, UK) following manufacturers steps. PDE5A (Oa04859755_m1) and NPPB (Oa04931155_g1) mRNA abundance was determined using Taqman single tube FAM-MGB assays (ThermoFisher, UK) following the manufacturers protocols and normalized to either RPLPO alone (Oa04824512_g1) or TBP (Oa0481075_m1) and YWHAZ (Oa03216375_gH) combined using the 2 -ΔΔC t method (Supplemental Information, Figure S2 ). All qPCR experiments were repeated 3 times and data averaged. For AmpII (BIN1) isoform determination the variably expressed region between exon 6 and exon 18 (Supplemental Information, Figure S3 ) was assessed using standard PCR approaches using primers (Eurofins, 
Isolation of Neonatal Rat Ventricular Myocyte, induced pluripotent stem cell cardiac myocyte culture and AmpII overexpression
Neonatal rat ventricular myocytes (NRVMs) were isolated from 2 day old Wistar rats and plated onto 8 well plates (Ibidi µ-plates; Thistle Scientific UK) at a density of ~ 3 x 10 5 cells/ml in media (containing: DMEM, 68 %, M199, 17 %; normal horse serum, 10 %; fetal bovine serum, 5 %; all Gibco Life Technologies, UK). Fungizone, Penicillin (10,000 units/ml) and streptomycin (10 mg/ml) were added to a final concentration of 1 % and bromodeoxyuridone (100 µmol/l) added to retard fibroblast proliferation. Human induced pluripotent stem cell derived cardiac myocytes (iPSC CMs) were purchased (Cellular Dynamics International, USA) and stored in liquid nitrogen until use. Cells were thawed, plated (~6 x 10 4 cells/cm 2 ) and maintained as per the manufacturer's instructions and using the manufacturers supplied media (iCell cardiomyocyte plating and culture media). Media was changed every 2 days. Five days after plating cells were transfected as described for NRVMs. Tubular structures were quantified by determining the fractional area as described above. legends. Survival data and Cox's proportional hazard ratios were also assessed using Stata ('stcox'). Linear regressions were fitted to non-paired data (Fig 5) by simulating 1000 randomly sampled (7 points in each condition without replacement) data subsets and fitting each of these with a linear regression. The mean slope and 95 % confidence limits were then obtained and superimposed on the plotted mean ± SEM data points. All values were considered significant when p < 0.05.
Determination of plasma tadalafil concentration and plasma protein binding
Data & Code Availability
The data that support the findings of this study are available from the corresponding author on reasonable request. Similarly, computer code (IDL) used for assessment of TT density are available from the corresponding author on reasonable request. 
